Table 3. Baseline and follow-up Characteristics
  Number of
observations
Group I Group II Group III Group IV P-value
N 351 103 65 89 94  
Age 351 32.18±4.49 32.72±4.02 31.41±4.03 31.82±4.14 .26
BMI, Kg/m2 351 25.63±4.04 25.43±3.71 24.85±3.67 24.79±3.99 .35
Factor (n,%) 351         .14
Male   27(26.21) 13(20) 19(21.35) 17(18.09)  
PCOS   9(8.74) 3(4.62) 11(12.36) 2(2.13)  
Tubal   34(33.01) 24(36.92) 36(40.45) 41(43.62)  
Endometriosis   21(20.39) 10(15.38) 14(15.73) 18(19.15)  
Others   12(11.65) 15(23.08) 9(10.11) 16(17.02)  
Type (n,%) 351         .88
Primary   96(93.20) 62(95.38) 82(92.13) 87(92.55)  
Secondary   7(6.80) 3(4.62) 7(7.87) 7(7.45)  
AFC 351 6.32±2.53 4.88±1.82 6.77±2.90 5.14±2.40 < .05
AMH, U/L
(median, range)
351 2.97
(.48-12.4)
2.8
(.28-6.99)
2.95
(.8-24.62)
2.95
(.8-24.62)
.25
FSH, IU/L 351 4.94±1.03 7.96±1.21 5.24±1.05 8.69±1.76 < .05
LH, IU/L 351 3.04±.80 3.27±.83 7.40±3.77 7.42±3.63 < .05
FSH,
starting dose, IU
351 284.44±
79.29
320.72±
79.01
268.97±
91.15
316.91±
88.25
< .05
FSH,
total dose, IU
351 3085.14±
963.21
3692.09±
1114.65
3105.30±
1414.68
3625.59±
1124.18
< .05
Endometrial thickness 351 9.66±1.74 9.08±1.71 9.31±1.66 8.78±2.20 < .05
Total days of stimulation 351 9.82±1.55 10.2±2.04 10.05±1.81 10.45±1.73 .09
Estradiol prior
to pick-up, pg/ml
351 3119.48±
2046.65
2002.83±
1181.49
3489.43±
2190.06
2674.80±
1740.52
< .05
Progesterone prior
to pick-up, ng/ml
273 1.13±.94 1.34±1.57 1.17±.87 1.15±.67 .79
Oocytes retrieved
(median, range)
351 10(1-28) 6(1-21) 11(2-31) 8(1-32) < .05
Mature oocytes
(median, range)
351 6(1-18) 3(1-14) 6(0-25) 5(0-24) < .05
Number of embryos
(median, range)
351 5(1-18) 4(1-16) 7(1-17) 4(1-20) < .05
Grade I embryos
(median, range)
351 3(1-18) 3(0-12) 5(1-17) 3(0-20) < .05
Pregnancy outcome 351         .36
No Pregnancy   67(65.05) 52(80.00) 68(76.40) 72(76.60)  
Biochemical or Miscarriage   6(5.83) 3(4.62) 4(4.49) 7(7.45)  
Ongoing   17(16.50) 6(9.23) 11(12.36) 6(6.38)  
Delivered   13(12.62) 4(6.15) 6(6.74) 9(9.57)